Showing 6681-6690 of 10161 results for "".
- Almirall: Phase 3 Studies of KX2-391 for AK Meet Primary Endpointshttps://practicaldermatology.com/news/almirall-phase-3-studies-of-kx2-391-for-ak-meet-primary-endpoints/2457676/Both Phase 3 studies of KX2-391met the primary endpoint of complete clearance of actinic keratosis (AK) lesions at day 57 within the face or scalp treatment areas, Almirall, SA reports. Each study achieved statistical significance on this endpoint. The double-blind, randomized, vehi
- New Applicator Suggests Cryolipolysis May Be an Option for Male Pseudogynecomastiahttps://practicaldermatology.com/news/new-applicator-suggests-cryolipolysis-may-be-an-option-for-male-pseudogynecomastia/2457678/Thanks to a conformable surface applicator, cryolipolysis can be a safe and effective way to treat male pseudogynecomastia, according to a recent study in Lasers in Surgery and Medicine (LSM). “This split-b
- TruDerm Adds Second Dermatology Centerhttps://practicaldermatology.com/news/truderm-adds-second-dermatology-center/2457681/
- Skin Cancer Foundation Accepting Grant Applicationshttps://practicaldermatology.com/news/skin-cancer-foundation-accepting-grant-applications/2457690/The Skin Cancer Foundation is now accepting applications for support of pilot research projects related to skin cancer. Two grants of $50,000 and one grant of $25,000 will be awa
- New From InMode: Triton Multi-Wavelength Hair Removal Laserhttps://practicaldermatology.com/news/new-from-inmode-triton-multi-wavelength-hair-removal-laser/2457698/InMode Ltd. is launching the Triton hair removal device. Recently cleared by the FDA, Triton is the first and only high power laser to offer simultaneous multi-wavelength hair removal firing, allowing concurrent emissions of Alexandrite, Diode, and Nd:YAG wavelengths. The company say
- Sensus Healthcare Forms Strategic Agreement with SkinCure Oncologyhttps://practicaldermatology.com/news/sensus-healthcare-forms-strategic-agreement-with-skincure-oncology/2457697/Sensus Healthcare, Inc., which specializes in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), formed a strategic agreement focused on marketing the SRT-100 Vision with SkinCure Oncology, a leading turnkey provider
- Rare Pediatric Skin Conditions Often Get Expensive, Inconsistent Carehttps://practicaldermatology.com/news/rare-pediatric-skin-conditions-often-get-expensive-inconsistent-care/2457704/Children with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have high rates of complications — resulting in long and costly hospital stays — and that treatment strategies varied among health care providers, according to the first large-scale analysis, which is
- PAH after Cryolipolysis May Not Be So 'Rare'https://practicaldermatology.com/news/pah-after-cryolipolysis-may-not-be-so-rare/2457707/Paradoxical adipose hyperplasia (PAH) after cryolipolysis may be more common than previously thought according to a paper in the July issue of Plastic and Reconstructive Surgery®. While PAH can be treated successfully
- BrightGuard Installs Free Sunscreen Dispensers at New York City Public Pools and Beacheshttps://practicaldermatology.com/news/brightguard-installs-free-sunscreen-dispensers-at-new-york-city-public-pools-and-beaches/2457708/Through its ongoing partnership with non-profit sponsor and donor IMPACT Melanoma and sunscreen provider Coppertone, BrightGuard has installed 134 sunscreen dispensers throughout New York City (NYC) public pools and beaches. BrightGuard—the first aut
- FDA Approves Dermira's Qbrexza Cloth to Treat Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/fda-approves-delmiras-qbrexza-cloth-to-treat-primary-axillary-hyperhidrosis/2457709/The FDA has approved Qbrexza™ (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Qbrexza is applied directly to the skin and is designed to block sweat production by inhib